Home / Departments & Hospitals / Scientific Working groups / MOLECULAR ONCOLOGY / HEMATOLOGY


“To identify novel molecular targets in order to develop innovative therapeutic cancer agents and translate them into the clinics”

Our laboratory is interested in both the basic elucidation of signaling pathways leading to tumor cell growth, proliferation, migration and drug resistance within the tumor microenvironment as well as its translation into potential future therapeutic approaches, with a particular focus on Multiple Myeloma and Breast Cancer. Our previous work has defined the pathophysiologic role of VEGF, PKCs, Src/ Hck, lipid rafts/ caveolin, Mcl-1, and the transcription factors cJun and JunB in Multiple Myeloma. These basic studies contributed to the clinical development of the IMiDs (Lenalidomide, Pomalidomide), proteasome inhibitors (Bortezomib, Marizomib), and most recently monoclonal antibodies (Daratumumab, Elotuzumab). Moreover, derived clinical trials have also evaluated the therapeutic role of anti- angiogenic compounds alone or in combination with other novel and conventional therapies to improve patient outcome; studies on the VEGF receptor inhibitor Pazopanib have stimulated the its clinical approval in renal cell carcinoma.


  1. 03 Nov

    KL Lunchtime Seminar: On the Physiological Role of Store-Operated Calcium Entry in Skeletal Muscle

    03. November 2021, 12:00 - 13:00
    Karl Landsteiner University, 3500 Krems/Donau, Wing Y, KL Auditorium